Hyperglycemia crisis in head and neck cancer patients with platinum-based chemotherapy

The development of a hyperglycemic crisis in platinum-based chemotherapy-treated head and neck cancer patients, such as hyperosmolar hyperglycemic state (HHS), has been reported. Hyperglycemic crises are associated with a high risk of comorbidity and may delay cancer treatment if not promptly managed. This is a retrospective study using cancer registry data from a tertiary medical center. Head and neck cancer patients who had been treated with platinum-based chemotherapy from January 2014 to December 2015 were enrolled for review. Exclusion criteria included patients with a known history of type 2 diabetes mellitus (DM). Characteristics of patients who developed type 2 DM after initiation of chemotherapy were compared with non-DM patients, following which the clinical course of the patients developing a hyperglycemic crisis were reviewed. A total of 185 patients were enrolled, of which seven patients (3.8%) had developed type 2 DM after initiation of platinum-based chemotherapy. No statistically significant differences in age, body mass index, sex, cancer subsite, cancer stage, or chemotherapy regimen were found when comparing new-onset type 2 DM patients with the rest of the patients. Three patients developed diabetic ketoacidosis, HHS, or impending HHS after initiating chemotherapy treatment. The incidence of hyperglycemic crises was 3 out of 185 (1.6%) in this patient group. Hyperglycemic crisis after cisplatin may be underestimated and may lead to a life-threatening condition. We suggest regular weekly follow-ups of serum glucose level after platinum-based chemotherapy for early detection of hyperglycemia and prevention of a life-threatening crisis.